TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2026)

TransMedics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 71.32% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 36.22% YoY), while the FY2025 annual figure was $1.1 billion, up 32.87% from the prior year.
• Liabilities and Shareholders Equity was $1.4 billion for Q1 2026 at TransMedics, up from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $117.3 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $671.5 million across 5 years, with a median of $723.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity dropped 16.53% in 2022, then soared 488.62% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $277.1 million in 2022, then soared by 154.76% to $706.0 million in 2023, then rose by 13.88% to $804.1 million in 2024, then surged by 32.87% to $1.1 billion in 2025, then surged by 34.3% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $946.0 million (Q3 2025), per Business Quant data.